San Anselmo M, Lantero E, Avalos-Padilla Y, Bouzon-Arnaiz I, Ramirez M, Postigo A
ACS Appl Polym Mater. 2023; 5(1):381-390.
PMID: 36686062
PMC: 9844211.
DOI: 10.1021/acsapm.2c01553.
Burzynska P, Jodlowska M, Zerka A, Czujkowski J, Jaskiewicz E
Biomolecules. 2022; 12(11).
PMID: 36421683
PMC: 9687201.
DOI: 10.3390/biom12111669.
Zang L, Zhu H, Wang K, Liu Y, Yu F, Zhao W
Molecules. 2022; 27(20).
PMID: 36296562
PMC: 9609994.
DOI: 10.3390/molecules27206968.
Burns A, Dans M, Balbin J, de Koning-Ward T, Gilson P, Beeson J
FEMS Microbiol Rev. 2019; 43(3):223-238.
PMID: 30753425
PMC: 6524681.
DOI: 10.1093/femsre/fuz005.
Saiwaew S, Sritabal J, Piaraksa N, Keayarsa S, Ruengweerayut R, Utaisin C
PLoS One. 2017; 12(3):e0172718.
PMID: 28249043
PMC: 5332063.
DOI: 10.1371/journal.pone.0172718.
Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery.
Marques J, Valle-Delgado J, Urban P, Baro E, Prohens R, Mayor A
Nanomedicine. 2016; 13(2):515-525.
PMID: 27720930
PMC: 5332526.
DOI: 10.1016/j.nano.2016.09.010.
Rosette-Disrupting Effect of an Anti-Plasmodial Compound for the Potential Treatment of Plasmodium falciparum Malaria Complications.
Chng J, Moll K, Del Pilar Quintana M, Chun Leung Chan S, Masters E, Moles E
Sci Rep. 2016; 6:29317.
PMID: 27403804
PMC: 4941523.
DOI: 10.1038/srep29317.
Marine organism sulfated polysaccharides exhibiting significant antimalarial activity and inhibition of red blood cell invasion by Plasmodium.
Marques J, Vilanova E, Mourao P, Fernandez-Busquets X
Sci Rep. 2016; 6:24368.
PMID: 27071342
PMC: 4829872.
DOI: 10.1038/srep24368.
Combating malaria with nanotechnology-based targeted and combinatorial drug delivery strategies.
Thakkar M, S B
Drug Deliv Transl Res. 2016; 6(4):414-25.
PMID: 27067712
DOI: 10.1007/s13346-016-0290-2.
Fucosylated chondroitin sulfate inhibits Plasmodium falciparum cytoadhesion and merozoite invasion.
Bastos M, Albrecht L, Kozlowski E, Lopes S, Blanco Y, Carlos B
Antimicrob Agents Chemother. 2014; 58(4):1862-71.
PMID: 24395239
PMC: 4023758.
DOI: 10.1128/AAC.00686-13.
Maternal malaria induces a procoagulant and antifibrinolytic state that is embryotoxic but responsive to anticoagulant therapy.
Avery J, Smith G, Owino S, Sarr D, Nagy T, Mwalimu S
PLoS One. 2012; 7(2):e31090.
PMID: 22347435
PMC: 3274552.
DOI: 10.1371/journal.pone.0031090.
Low anticoagulant heparin disrupts Plasmodium falciparum rosettes in fresh clinical isolates.
Leitgeb A, Blomqvist K, Cho-Ngwa F, Samje M, Nde P, Titanji V
Am J Trop Med Hyg. 2011; 84(3):390-6.
PMID: 21363975
PMC: 3042813.
DOI: 10.4269/ajtmh.2011.10-0256.
Release of sequestered malaria parasites upon injection of a glycosaminoglycan.
Vogt A, Pettersson F, Moll K, Jonsson C, Normark J, Ribacke U
PLoS Pathog. 2006; 2(9):e100.
PMID: 17009869
PMC: 1579244.
DOI: 10.1371/journal.ppat.0020100.
Growth-inhibitory effect of heparin on Babesia parasites.
Bork S, Yokoyama N, Ikehara Y, Kumar S, Sugimoto C, Igarashi I
Antimicrob Agents Chemother. 2003; 48(1):236-41.
PMID: 14693545
PMC: 310193.
DOI: 10.1128/AAC.48.1.236-241.2004.
Steroids for treating cerebral malaria.
Prasad K, Garner P
Cochrane Database Syst Rev. 2000; (2):CD000972.
PMID: 10796562
PMC: 6532619.
DOI: 10.1002/14651858.CD000972.
Exotic disease.
Br Med J. 1971; 3(5765):1-2.
PMID: 4933387
PMC: 1800112.
Malaria risk to travellers.
Br Med J. 1973; 1(5855):691-2.
PMID: 4694687
PMC: 1588885.
Malaria in the United Kingdom.
BRUCE-CHWATT L, SOUTHGATE B, Draper C
Br Med J. 1974; 2(5921):707-11.
PMID: 4604717
PMC: 1611114.
DOI: 10.1136/bmj.2.5921.707.
Antibodies to a histidine-rich protein (PfHRP1) disrupt spontaneously formed Plasmodium falciparum erythrocyte rosettes.
Carlson J, Holmquist G, Taylor D, Perlmann P, Wahlgren M
Proc Natl Acad Sci U S A. 1990; 87(7):2511-5.
PMID: 2108439
PMC: 53719.
DOI: 10.1073/pnas.87.7.2511.
The treatment of malaria.
HALL A
Br Med J. 1976; 1(6005):323-8.
PMID: 764937
PMC: 1638678.
DOI: 10.1136/bmj.1.6005.323.